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WHO. 2003. ISBN 92-4-154601-8. (Available from SAMA-HMPG.
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Clinicians, academics, funders, policy makers, consumers and
ethnicists have all been sensitised to the need for evidence when
making decisions in the adoption of health interventions.
Evidence-based medicine relies on comprehensive analysis of
scientifically valid studies covering sufficient subjects, with the
proviso that both positive and negative results have been included
in the analytical process. However, all this is not enough: to
ultimately decide whether or not to adopt an intervention one is
also obliged to consider the health economics of the situation.
Whether introducing an intervention where none existed before,
adding a second to complement an existing intervention, or
seeking the right balance in terms of competing interventions, one
needs to fully understand the dimensions of cost and
effectiveness.
This WHO Guide to Cost Effectiveness Analysis is an eminently
readable text that not only covers basic concepts for the novice
who is simply seeking to understand the field, but also provides a
set of background papers and applications. These include scientific
papers by international experts in the fields of population
modelling, communicating cost-effectiveness results to decision
makers, and examples of specific health interventions. A mini-CD
is also included with the book, and this will provide hands-on
experience for those who wish to actually process cost data,
calculate the effectiveness of interventions for a standardised
population, or understand levels of uncertainty around costs and
effects.
For the average reader, the first half of the book will be of great
value in developing an understanding of how to rank
interventions and decide on appropriate cost-effective mixes for a
given set of conditions in a specific environment. Cost estimation
is covered in detail, as is the full estimation of health effects. Yes,
there may well be more comprehensive health economics reference
sources that give much more in the way of definitions and
alternative methods of determining impact of interventions, but
this is certainly one that will not intimidate the uninitiated and
will also appeal to the more advanced user.
Alan Rothberg
Controlling Disease due to Helminth
Infections
Edited by DWT Crompton, A Montressor, MC Nesheim and L
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This should be a handbook for health professionals and
administrators who are working in child, women’s, school,
public and environmental health. For specialists in education, it
explains how worm infestation can impair learning, and why
the school system is a key to implementation of control. It is
school-age children and young women who carry the greatest
burden of morbidity and disease due to infestation by parasitic
worms. The planning, implementation, management and
monitoring of control and prevention are described. That
success is feasible has been proved by Japan and Korea, and
other countries are making substantial progress.
This book is also about World Health Assembly resolution
54.19 of May 2001, which South Africa supported. It calls on
member states to control soil-transmitted helminthiasis and
schistosomiasis. One target is that there should be regular
deworming of at least 75% of school-age children by 2010
because this is the quickest way to counter morbidity and
improve learning. School-based treatment frequency should be
determined by the degree of exposure to infection through lack
of sanitation. However, South Africa still has no national
control programme or achievable policy. Red tape and
bureaucracy are frustrating attempts to initiate control. Strictly
speaking, school-based, mass deworming may be illegal. The
same goes for buying anthelminthics for as little as 11 cents a
dose offshore, as advocated by WHO. One of the
anthelminthics of choice, which is completely safe, is a
schedule 4 medicine. This may be more profitable but blocks
lawful use for non-selective deworming. It is fundamental that
the main-line anthelminthics are safe for use in young children
and after the first trimester of pregnancy but this is not in the
package inserts. This disinformation by the pharmaceutical
industry has a strong negative influence on paramedics and lay
people who have to implement deworming.
Unfortunately there are serious typographical errors in
the first edition, especially in some tables and figures. There
also appears to be a conflict of interest in favour of albendazole
in the chapter on anthelminthics, by John Horton.
John Fincham
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